The race to develop the next wave of obesity drugs in development just got more competitive. Metsera's lead candidate, MET-097i, is a fully biased, ultra-long-acting GLP-1 receptor agonist engineered on the company's proprietary HALO platform. With a half-life of 15–16 days, it holds the potential to become the first-ever once-monthly injectable for chronic weight management — a meaningful step up from today's weekly regimens.
In two Phase I/II presentations at ADA 2025, MET-097i demonstrated robust, dose-dependent weight loss. In the 12-week study, the 1.2 mg weekly dose delivered a placebo-corrected weight reduction of –11.3% at Day 85, with no plateau in sight. Following a single high-dose monthly injection, weight loss extended to –15.0% by Day 115 — a result that underscores how new obesity drugs in development are pushing efficacy boundaries further with each new generation.
Beyond weight loss, MET-097i also delivered meaningful improvements in cardiometabolic markers — including reductions in LDL cholesterol, total cholesterol, and systolic blood pressure — signaling broader therapeutic value. The safety profile remained consistent with the GLP-1 drug class, with mild, transient GI effects and no treatment-related discontinuations, reinforcing the growing confidence around the obesity market opportunity for long-acting agents.
As the obesity market size continues to expand globally — driven by surging demand for effective and convenient therapies — MET-097i's monthly dosing potential could differentiate it sharply from current standards of care. Its predictable pharmacokinetics, with dose-proportional plasma levels and an accumulation ratio of ~3 after five weekly doses, give it a clean and manageable clinical profile.
For stakeholders tracking the obesity pipeline, MET-097i represents one of the more compelling near-term catalysts to watch. Ongoing Phase IIb studies exploring both weekly and monthly dosing regimens will be pivotal in confirming long-term durability and determining its competitive standing against rivals — including assets tracked under the eli lilly obesity pipeline and other innovators racing toward commercialization.
With compelling early data, a differentiated mechanism, and a patient-friendly dosing profile, MET-097i is firmly establishing itself as one of the most exciting candidates in the next generation of GLP-1 therapies.
About Delveinsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk